2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Animal Model
PAPER

5032 Novel acute lymphoblastic leukemia cell line models reveal subtype-specific genetic and pharmacologic vulnerabilities

Yiming Wu, PhD, Haider Inam2, Katarzyna Anna Szoltysek, PhD3, Ilaria Iacobucci, PhD4, Landon Choi, MS5, Carmen Rios6, Pankaj Ghate, PhD7, Bo Zhang, PhD8, Yunchao Chang, PhD9, Qingsong Gao, PhD10, Petri Polonen, PhD11, Emily Backhaus12, Xiao Zheng13, Meng Horng Lee14, Yuan Feng15, Pooja Singh16, Kami Chauncy17, Huan Zhang18, Tanya Khan19, Tony Brown20, Amanda Brewer21, Sandi Radko-Juettner, PhD22, Ruth Wang'ondu23, Kathryn G. Roberts, PhD24, Kristine R Crews, PharmD25, Moony Tseng26, Xiaotu Ma, PhD27, Jun J. Yang, PhD28, Francisca Vazquez, PhD29, Charles G. Mullighan, MBBS (Hons), MSc, MD30
1 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
2 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
3 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
4 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
5 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
6 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
7 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
8 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
9 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
10 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
11 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
12 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
13 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
14 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
15 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
16 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
17 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
18 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
19 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
20 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
21 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
22 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
23 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
24 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
25 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
26 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
27 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
28 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States
29 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States
30 St. Jude Children’s Research Hospital, Memphis, Tennessee, United States

Background
Pediatric acute lymphoblastic leukemia (ALL) comprises diverse genetic subtypes, but existing cell lines are heavily biased toward a few subtypes, limiting systematic dependency discovery in high-risk and underrepresented leukemias. To address this gap, we developed a platform to generate leukemia cell lines and identify subtype-specific vulnerabilities through CRISPR and drug screening as part of the Pediatric Cancer Dependency Map (PedDep) project.

Methods
Patient-derived xenograft (PDX) ALL samples were co-cultured with primary mesenchymal stromal cells in SFEM II medium and subsequently adapted to stromal-free growth conditions. All models were characterized by short tandem repeat profiling, whole-genome sequencing, and transcriptome sequencing. The resulting lines were used for genome-wide CRISPR screening and four-day imaging-based pharmacologic screening with a 40-drug panel comprising conventional ALL chemotherapies and targeted agents against kinase signaling, apoptotic pathways, and nucleotide metabolism.

Results
Using this approach, we established 63 B-ALL and 15 T-ALL cell lines from 135 attempts, each derived from a unique PDX sample. We confirmed that the derived models retained the genetic identity and key genomic and transcriptomic features of their matched PDX samples. These lines represented 14 B-ALL subtypes, including low hypodiploid (n=11), HLF-rearranged (-r; n=7), PAX5alt (n=7), BCR::ABL1-like (n=6), ZEB2/CEBP-r (n=4), and iAMP21 (n=1), as well as seven T-ALL subtypes, including ETP-like (n=5), SPI1-r (n=1), and BCL11B::FOXF1 (n=1).

Genome-wide CRISPR screens were completed in 40 B-ALL lines, including six low hypodiploid and five HLF-r models, with an additional 28 lines in progress. Expected genetic driver-associated dependencies were identified, supporting the validity of the platform. RAS-MAPK signaling emerged as a recurrent vulnerability with distinct upstream drivers across subtypes: ABL1-r lines were dependent on ABL1, HLF-r lines on NRAS or KRAS, and ZNF384-r and FLT3-altered lines on FLT3. All screened low hypodiploid lines showed selective dependency on insulin receptor (INSR), the strongest hit in this subtype, which is potentially druggable and showed no significant dependency across other cancer cell lines. HLF-r lines also showed strong dependencies on PTEN and PI3K regulatory subunits. Although these genes are negative regulators of PI3K-AKT signaling, these findings suggest that perturbation of this regulatory balance may create a therapeutic vulnerability in HLF-r B-ALL. Low hypodiploid models showed strong dependencies on cell-cycle checkpoint regulators, including Cyclin D-CDK4/6 for G1/S progression or Cyclin A/B-CDK1 for S/G2/M progression, as well as mitotic machinery. We further identified subtype-enriched dependencies in DNA repair pathways, most prominently in BCR::ABL1-positive and HLF-r lines, including homologous recombination, Fanconi anemia pathway components, and genes involved in R-loop resolution, suggesting increased vulnerability to replication-associated DNA damage. Folate-, heme-, and lipid-related metabolic dependencies were also identified in previously underrepresented subtypes, including ZEB2/CEBP-r, BCL6-r, and IKZF1 N159Y models.

Drug sensitivity profiles were concordant between PDXs and matched derived cell lines (n=7) across the 40-drug panel, with R² values ranging from 0.5 to 0.8, supporting the use of these models for therapeutic discovery. Expanded pharmacotyping of 47 newly generated ALL lines revealed subtype-associated sensitivities, including the MCL1 inhibitors AZD5991 and S63845 and MEK inhibition in PAX5alt lines; BCL2 inhibition and vincristine in low hypodiploid, near haploid, and hyperdiploid lines; purine analog sensitivity in HLF-r lines; and multi-RTK inhibitor sensitivity, particularly to gilteritinib, in FLT3-altered lines. These findings were consistent with the CRISPR screen results.

Conclusions
We established and validated a diverse panel of leukemia cell line models spanning high-risk and previously underrepresented ALL subtypes. Integration of genome-wide CRISPR screening and pharmacotyping identified subtype-specific genetic and drug dependencies, many of which are potentially therapeutically actionable. This scalable model platform enables systematic functional discovery and may accelerate the development of new therapeutic strategies for high-risk acute leukemia.

Yiming Wu, PhD: No relevant conflicts of interest to declare.